{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:48:48Z","timestamp":1792838928441,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.atherosclerosis.2006.11.036","type":"journal-article","created":{"date-parts":[[2007,1,23]],"date-time":"2007-01-23T12:58:09Z","timestamp":1169557089000},"page":"293-299","source":"Crossref","is-referenced-by-count":142,"title":["Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: A systematic review"],"prefix":"10.1016","volume":"194","author":[{"given":"Alexey","family":"Sorokin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis","volume":"353","author":"Kaplan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","article-title":"The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis","volume":"128","author":"Corpechot","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib3","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib4","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/ije\/26.4.830","article-title":"Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne","volume":"26","author":"Metcalf","year":"1997","journal-title":"Engl Int J Epidemiol"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/00365529850166284","article-title":"Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population","volume":"33","author":"Boberg","year":"1998","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib6","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1089-3261(03)00100-4","article-title":"Natural history of primary biliary cirrhosis","volume":"7","author":"Pares","year":"2003","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0168-8278(05)80139-4","article-title":"Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years","volume":"20","author":"Mahl","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/gut.46.1.121","article-title":"Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment","volume":"46","author":"Leuschner","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib9","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1055\/s-2005-858281","article-title":"Ursodeoxycholic acid in the therapy for primary biliary cirrhosis: effects on progression and prognosis","volume":"43","author":"Leuschner","year":"2005","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib10","first-page":"89","article-title":"Metabolism of cholesterol and low- and high-density lipoproteins in primary biliary cirrhosis: cholesterol absorption and synthesis related to lipoprotein levels and their kinetics","volume":"21","author":"Gylling","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib11","first-page":"364","article-title":"Changes in the lipid profile in chronic hepatopathies","volume":"102","author":"Perales","year":"1994","journal-title":"Med Clin (Barc)"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2006.11.036_bib12","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003088-200544050-00002","article-title":"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions","volume":"44","author":"Kosoglou","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib13","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1194\/jlr.M400229-JLR200","article-title":"Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation","volume":"45","author":"Chang","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib14","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1172\/JCI108393","article-title":"Formation of lipoprotein-X. Its relationship to bile compounds","volume":"57","author":"Manzato","year":"1976","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib15","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/0016-5085(85)90642-0","article-title":"Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification","volume":"89","author":"Jahn","year":"1985","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib16","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/0016-5085(90)90356-6","article-title":"Hyperviscosity syndrome in a hypercholesterolemic patient with primary biliary cirrhosis","volume":"98","author":"Rosenson","year":"1990","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2006.11.036_bib17","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1172\/JCI111504","article-title":"Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein-X and its effect on 3-hydroxy-3-methylglutaryl coenzyme A reductase and chylomicron remnant removal in human fibroblasts, lymphocytes, and in the rat","volume":"74","author":"Walli","year":"1984","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib18","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0026-0495(93)90051-O","article-title":"Lipoprotein-X fails to inhibit hydroxymethylglutaryl coenzyme A reductase in HepG2 cells","volume":"42","author":"Edwards","year":"1993","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib19","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/BF01536666","article-title":"Lipoprotein pattern and plasma lipoprotein lipase activities in patients with primary biliary cirrhosis. Relationship with increase of HDL2 fraction in Lp-X-positive and Lp-X-negative subjects","volume":"33","author":"Baldo-Enzi","year":"1988","journal-title":"Digest Dis Sci"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib20","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0950-351X(05)80080-1","article-title":"Dyslipoproteinaemia of liver disease","volume":"4","author":"Miller","year":"1990","journal-title":"Baillieres Clin Endocrinol Metab"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib21","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0022-2275(20)37713-0","article-title":"High density lipoprotein metabolism","volume":"25","author":"Eisenberg","year":"1984","journal-title":"J Lipid Res"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2006.11.036_bib22","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0022-2275(20)37730-0","article-title":"Abnormal high density lipoproteins from patients with liver disease regulate cholesterol metabolism in cultured human skin fibroblasts","volume":"25","author":"Owen","year":"1984","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib23","first-page":"369","article-title":"Lecithin-cholesterol acyltransferase and the lipoprotein abnormalities of obstructive jaundice.","volume":"54","author":"Agorastos","year":"1978","journal-title":"Clin Sci Mol Med"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2362.1974.tb00415.x","article-title":"Hypertriglyceridaemia secondary to liver disease","volume":"4","author":"Muller","year":"1974","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hep.1840180117","article-title":"Decrease of hepatic triglyceride lipase levels and increase of cholesteryl ester transfer protein levels in patients with primary biliary cirrhosis: relationship to abnormalities in high-density lipoprotein","volume":"18","author":"Hiraoka","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/gut.51.2.265","article-title":"Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis","volume":"51","author":"Longo","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib27","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/hep.1840150518","article-title":"Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk?","volume":"15","author":"Crippin","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/00365529709025067","article-title":"Primary biliary cirrhosis in The Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures","volume":"32","author":"Van Dam","year":"1997","journal-title":"Scand J Gastroenterol"},{"issue":"6 Pt. 2","key":"10.1016\/j.atherosclerosis.2006.11.036_bib29","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1172\/JCI102222","article-title":"The relationship between serum lipids and skin xanthomata in 18 patients with primary biliary cirrhosis","volume":"28","author":"Ahrens","year":"1949","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib30","unstructured":"Ladd, Kellner AT. Intravenous detergents in experimental atherosclerosis, with special reference to the possible role of phospholipids. Fed Proc 1949."},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib31","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0168-8278(02)00006-5","article-title":"Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers","volume":"36","author":"Ritzel","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib32","first-page":"1187","article-title":"Marked improvement in cholestasis and hypercholesterolemia with simvastatin in a patient with primary biliary cirrhosis","volume":"90","author":"Kamisako","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib33","first-page":"890","article-title":"Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia","volume":"15","author":"Kurihara","year":"1993","journal-title":"Clin Ther"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0022-2275(20)31668-0","article-title":"Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration","volume":"42","author":"Del Puppo","year":"2001","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0939-4753(04)80008-5","article-title":"Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits","volume":"14","author":"Anfossi","year":"2004","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib36","first-page":"233","article-title":"Acute cholestatic hepatitis during simvastatin administration","volume":"82","author":"Ballare","year":"1991","journal-title":"Recent Prog Med"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib37","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1055\/s-2008-1055341","article-title":"Lovastatin-induced acute cholestatic hepatitis","volume":"120","author":"Huchzermeyer","year":"1995","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib38","doi-asserted-by":"crossref","unstructured":"Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006.","DOI":"10.1016\/j.amjcard.2005.12.007"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib39","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s11938-003-0051-4","article-title":"Management of primary biliary cirrhosis","volume":"6","author":"Levy","year":"2003","journal-title":"Curr Treat Opt Gastroenterol"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib40","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1111\/j.1572-0241.2000.03220.x","article-title":"Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid","volume":"95","author":"Kurihara","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib41","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3748\/wjg.v10.i6.894","article-title":"Fenofibrate for patients with asymptomatic primary biliary cirrhosis","volume":"10","author":"Dohmen","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib42","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1572-0241.2002.05413.x","article-title":"Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy","volume":"97","author":"Kurihara","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib43","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0025-6196(12)61815-1","article-title":"Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis","volume":"69","author":"Balan","year":"1994","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/00365529409103619","article-title":"Influence of ursodeoxycholic acid on biliary lipids","volume":"204","author":"Roda","year":"1994","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib45","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/0016-5085(90)90834-N","article-title":"Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids","volume":"98","author":"Stiehl","year":"1990","journal-title":"Gastroenterology"},{"issue":"Suppl. 12","key":"10.1016\/j.atherosclerosis.2006.11.036_bib46","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1007\/BF01536658","article-title":"Bile acid\u2013lipoprotein interactions: effects of ursodeoxycholic acid (ursodiol)","volume":"34","author":"Fromm","year":"1989","journal-title":"Digest Dis Sci"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib47","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0016-5085(19)30493-7","article-title":"Effect of high and low doses of ursodeoxycholic acid on gallstone dissolution in humans","volume":"78","author":"Salen","year":"1980","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2006.11.036_bib48","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/0016-5085(86)90708-0","article-title":"Effect of ursodeoxycholic acid and chenodeoxycholic acid on cholesterol and bile acid metabolism","volume":"91","author":"Tint","year":"1986","journal-title":"Gastroenterology"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915006007271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915006007271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T00:57:06Z","timestamp":1628384226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915006007271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0021915006007271"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2006.11.036","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}